Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants

Identification and Characterization of Commercial RUO Antibodies for the Detection of Specific Breast Cancer Tumoral Markers Expressed in Potential Circulating Tumoral Cells (CTCs)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05054010

Enrollment

Registered

2021-09-23

Start date

2021-10-04

Completion date

2026-12-01

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

Breast Cancer Biomarker, Circulating Tumoral Cell, Immunofluorescence Assay, Breast Cancer

Brief summary

This is an exploratory research study with the aim of identifying specific cancer biomarkers in various subtypes of breast cancer. Blood samples will be collected from 60 participants divided into 40 patients and 20 healthy donors. An amendment to the research has been proposed to enroll 24 additional participants divided into 12 patients and 12 healthy donors.

Detailed description

In this research study different commercial RUO (Research Use Only) antibodies will be purchased and then tested on blood samples obtained by participants affected by breast cancer and by healthy participants as control. Sixty participants will be enrolled belonging to different categories: 20 participants affected by early breast cancer, 20 participants affected by metastatic breast cancer, and 20 healthy volunteers to be used as negative control. After signing the informed consent form, participants will be screened to evaluate if they meet the eligibility criteria. If all the criteria are met, participants will be enrolled into the study and will be asked to provide some demographic and other data. A 13 ml blood sample will be collected by the subjects and shipped to Tethis laboratories in order to be processed and analysed. An amendment has been proposed to enroll 24 additional participants divided into 12 patients and 12 healthy donors. During the amendment, participants will be enrolled to test the analytical capacity of the antibodies evaluated in the first part on samples processed with different methods in order to select the optimal one for future development.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Participant is willing and able to give and sign a written informed consent for participation in the study. * Female aged 18 years or above. * Diagnosed with early breast cancer (stage I and II) or metastatic breast cancer. * Healthy participants who visit the site for reason other than cancer diagnosis (including breast cancer).

Exclusion criteria

* History of other malignancies other than breast cancer (for healthy participants includes also breast cancer). * Undergone surgery or treatment for breast cancer before enrollment (only for early breast cancer). * Presence of known severe coagulation or haematological disorder * Known Pregnancy * Absence of written signed informed consent for participation in the study

Design outcomes

Primary

Measure	Time frame	Description
Number of commercial Antibodies capable of Identify specific Breast Cancer Biomarkers	1 day (at the blood draw)	Qualitative Assessment of Staining Positivity for different Breast Cancer Biomarkers

Countries

Italy

Contacts

PRINCIPAL_INVESTIGATOROreste Gentilini, MD

Ospedale San Raffaele

Outcome results